Histone deacetylase inhibitor for NUT midline carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|62|4|715-717

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.4, 2015-04, pp. : 715-717

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Importance of Diagnosing NUT Midline Carcinoma

By French Christopher  

Head and Neck Pathology, Vol. 7, Iss. 1, 2013-03 ,pp. : 11-16

Humana Press, Inc

Access to resources Recommend Favorite

Cytologic findings of NUT midline carcinoma in the hilum of the lung

By  

DIAGNOSTIC CYTOPATHOLOGY, Vol. 43, Iss. 9, 2015-09 ,pp. : 739-742

John Wiley & Sons Inc

Access to resources Recommend Favorite

Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma

By            

International Journal of Molecular Medicine, Vol. 31, Iss. 2, 2013-01 ,pp. : 339-346

Spandidos Publications

Access to resources Recommend Favorite

Clinical Significance of Histone Deacetylase 1 Expression in Patients with Hepatocellular Carcinoma

By  

Oncology, Vol. 72, Iss. 1-2, 2007-11 ,pp. : 69-74

Karger

Access to resources Recommend Favorite

Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes

By Hara Naoko   Alkanani Aimon   Dinarello Charles   Zipris Danny  

Journal of Molecular Medicine, Vol. 92, Iss. 1, 2014-01 ,pp. : 93-102

Springer Publishing Company

Access to resources Recommend Favorite